Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
Neeraj NarulaEmily C L WongJohn K MarshallVipul JairathParambir S DulaiWalter ReinischPublished in: The American journal of gastroenterology (2022)
Patients with UC who achieve early PMS remission with vedolizumab have greater odds of week 52 remission compared with delayed responders.